138 related articles for article (PubMed ID: 23661306)
1. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients.
Stoehr R; Taubert H; Gaisa NT; Smeets D; Kneitz B; Giedl J; Ruemmele P; Wieland WF; Rau TT; Hartmann A
J Pathol; 2013 Aug; 230(4):453-6. PubMed ID: 23661306
[TBL] [Abstract][Full Text] [Related]
2. Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456.
Barbieri CE; Sboner A; Rubin MA; Garraway LA
J Pathol; 2013 Oct; 231(2):271. PubMed ID: 23729306
[No Abstract] [Full Text] [Related]
3. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
4. Mutation of
Yoon N; Lim S; Kang SY; Kwon GY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY
Asian J Androl; 2017; 19(3):346-349. PubMed ID: 26924278
[TBL] [Abstract][Full Text] [Related]
5. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Barbieri CE; Baca SC; Lawrence MS; Demichelis F; Blattner M; Theurillat JP; White TA; Stojanov P; Van Allen E; Stransky N; Nickerson E; Chae SS; Boysen G; Auclair D; Onofrio RC; Park K; Kitabayashi N; MacDonald TY; Sheikh K; Vuong T; Guiducci C; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Hussain WM; Ramos AH; Winckler W; Redman MC; Ardlie K; Tewari AK; Mosquera JM; Rupp N; Wild PJ; Moch H; Morrissey C; Nelson PS; Kantoff PW; Gabriel SB; Golub TR; Meyerson M; Lander ES; Getz G; Rubin MA; Garraway LA
Nat Genet; 2012 May; 44(6):685-9. PubMed ID: 22610119
[TBL] [Abstract][Full Text] [Related]
6. Frequent MED12 mutations in phyllodes tumours of the breast.
Yoshida M; Sekine S; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Ochiai A
Br J Cancer; 2015 May; 112(10):1703-8. PubMed ID: 25839987
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.
Lien HC; Huang CS; Yang YW; Jeng YM
Histopathology; 2016 Feb; 68(3):433-41. PubMed ID: 26109290
[TBL] [Abstract][Full Text] [Related]
8. Stromal
da Silva EM; Beca F; Sebastiao APM; Murray MP; Silveira C; Da Cruz Paula A; Pareja F; Wen HY; D'Alfonso TM; Edelweiss M; Weigelt B; Brogi E; Reis-Filho JS; Zhang H
J Clin Pathol; 2022 Feb; 75(2):133-136. PubMed ID: 33376197
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive screening for MED12 mutations in gynaecological mesenchymal tumours identified morphologically distinctive mixed epithelial and stromal tumours.
Yuan CT; Huang WC; Lee CH; Lin MC; Lee CH; Kao YC; Huang HY; Kuo KT; Lee JC
Histopathology; 2017 May; 70(6):954-965. PubMed ID: 28002623
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
11. MED12 exon 2 mutation is uncommon in intravenous leiomyomatosis: clinicopathologic features and molecular study.
Wang L; Hu S; Xin F; Zhao H; Li G; Ran W; Xing X; Wang J
Hum Pathol; 2020 May; 99():36-42. PubMed ID: 32240666
[TBL] [Abstract][Full Text] [Related]
12. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
[TBL] [Abstract][Full Text] [Related]
13. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.
Kämpjärvi K; Mäkinen N; Kilpivaara O; Arola J; Heinonen HR; Böhm J; Abdel-Wahab O; Lehtonen HJ; Pelttari LM; Mehine M; Schrewe H; Nevanlinna H; Levine RL; Hokland P; Böhling T; Mecklin JP; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2012 Nov; 107(10):1761-5. PubMed ID: 23132392
[TBL] [Abstract][Full Text] [Related]
14. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.
Lim WK; Ong CK; Tan J; Thike AA; Ng CC; Rajasegaran V; Myint SS; Nagarajan S; Nasir ND; McPherson JR; Cutcutache I; Poore G; Tay ST; Ooi WS; Tan VK; Hartman M; Ong KW; Tan BK; Rozen SG; Tan PH; Tan P; Teh BT
Nat Genet; 2014 Aug; 46(8):877-80. PubMed ID: 25038752
[TBL] [Abstract][Full Text] [Related]
15. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
16. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas.
McGuire MM; Yatsenko A; Hoffner L; Jones M; Surti U; Rajkovic A
PLoS One; 2012; 7(3):e33251. PubMed ID: 22428002
[TBL] [Abstract][Full Text] [Related]
17. MED12 mutations in human diseases.
Wang H; Shen Q; Ye LH; Ye J
Protein Cell; 2013 Sep; 4(9):643-6. PubMed ID: 23836153
[TBL] [Abstract][Full Text] [Related]
18. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
19. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases.
Ng CC; Tan J; Ong CK; Lim WK; Rajasegaran V; Nasir ND; Lim JC; Thike AA; Salahuddin SA; Iqbal J; Busmanis I; Chong AP; Teh BT; Tan PH
J Clin Pathol; 2015 Sep; 68(9):685-91. PubMed ID: 26018969
[TBL] [Abstract][Full Text] [Related]
20. MED12 exon 2 mutation as a highly sensitive and specific marker in distinguishing phyllodes tumours from other spindle neoplasms of the breast.
Lien HC; Huang CS; Yang YW; Jeng YM
APMIS; 2016 May; 124(5):356-64. PubMed ID: 26860948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
